Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
Published Online: 2022-09-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Anwen Liu•Baolan Li•Chengli Zhang•Cuimin Ding•David Ferry•Feng Ye•Hong Jian•Hui Zhou•Jian Fang•Jiuwei Cui•Ke Wang•Liang Han•Lin Wu•Liyun Miao•Meili Sun•Qiming Wang•Shun Lu•Shundong Cang•Shuyan Wang•Wen Zhang•Xing Sun•Xingya Li•Yanping Hu•Ying Chen•Yong Lin•Yueyin Pan•Ziping Wang
